{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:12:36Z","timestamp":1784128356292,"version":"3.55.0"},"reference-count":24,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T00:00:00Z","timestamp":1702252800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Veterinary Record"],"published-print":{"date-parts":[[2024,4,20]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Canine behaviour problems seen by speciality behavioural medicine services often involve chronic anxiety disorders that have resulted in maladaptation of the individual to its environment. Common stressors include the presence of other individuals (other dogs or people), noise and being alone. The treatment of these behavioural problems usually includes a combination of behaviour modification, environmental modification and biological therapies. Within the latter, anxiolytic drugs such as clomipramine or fluoxetine have proven useful.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Here, we present a retrospectively analysed series of 32 cases that were treated with the anxiolytic drug mirtazapine, which is widely used in human medicine but has not previously been reported for the treatment of behavioural problems in dogs (although it is marketed as an appetite stimulant in cats). Cases included dogs with a range of anxiety\u2010related behavioural problems.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Eighty\u2010one percent of dogs that presented with a behavioural problem showed improvement and suspected adverse effects were mild and tolerable.<\/jats:p>\n <\/jats:sec>\n \n Limitations<\/jats:title>\n Further studies are required to isolate this result from the other therapeutic measures and to compare its efficacy with other drugs.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Mirtazapine appears to be a suitable and safe option for the treatment of anxiety\u2010related behavioural problems in dogs.<\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/vetr.3670","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T15:26:44Z","timestamp":1702394804000},"source":"Crossref","is-referenced-by-count":3,"title":["Use of mirtazapine in the treatment of canine behaviour problems: A review of 32 cases"],"prefix":"10.1002","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4374-4654","authenticated-orcid":false,"given":"Juan","family":"Arg\u00fcelles","sequence":"first","affiliation":[{"name":"Cardenal Herrera\u2010CEU University Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Duque","sequence":"additional","affiliation":[{"name":"Ethoclinic Valencia Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Miralles","sequence":"additional","affiliation":[{"name":"Ethoclinic Valencia Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Bowen","sequence":"additional","affiliation":[{"name":"Queen Mother Hospital for Animals, Royal Veterinary College Hatfield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Fatjo","sequence":"additional","affiliation":[{"name":"Chair Affinity Foundation Animals and Health, Department of Psychiatry and Forensic Medicine Autonomous University of Barcelona Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,12,11]]},"reference":[{"key":"e_1_2_11_2_1","volume-title":"Manual of clinical behavioral medicine for dogs and cats","author":"Overall KL","year":"2013"},{"key":"e_1_2_11_3_1","volume-title":"Behavior problems of the dog and cat","author":"Landsberg G","year":"2013"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0195-5616(02)00101-8"},{"issue":"1","key":"e_1_2_11_5_1","first-page":"18","article-title":"Effects of reconcile (fluoxetine) chewable tablets plus behavior management for canine separation anxiety","volume":"8","author":"Simpson BS","year":"2007","journal-title":"Vet Ther"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.233.12.1902"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.5326\/0420407"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3458.2001.tb00198.x"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresbull.2004.02.007"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199512004-00004"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2008.12.022"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2013.09.078"},{"key":"e_1_2_11_13_1","article-title":"Mirtazapine versus other antidepressive agents for depression","volume":"12","author":"Watanabe N","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1601-5215.2006.00143.x"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2008.020"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.388"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781119226253"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jveb.2021.06.009"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvjl.2013.05.048"},{"key":"e_1_2_11_20_1","unstructured":"Arg\u00fcellesJ.Treatment of compulsive behaviour with mirtazapine and behaviour modification: clinical case.XVI AVEPA Specialities Congress Ethology Group Bilbao Spain. April2017."},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvjl.2011.05.010"},{"key":"e_1_2_11_22_1","unstructured":"Memoria RIVIA. 2022. Available from:https:\/\/www.rivia.org\/wp\u2010content\/uploads\/2023\/03\/Memoria_2022.pdf"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1017\/9781108975292"},{"key":"e_1_2_11_24_1","doi-asserted-by":"crossref","unstructured":"Arg\u00fcellesJ Enr\u00edquezJ BowenJ Fatj\u00f3J.Mirtazapine as a potential drug to treat social fears in dogs: five case examples.Proceedings of the 11th International Veterinary Behaviour Meeting. 14\u201317 September2017 Samorin Slovakia. Wallingford UK:CAB International;2017. p.84\u201385.","DOI":"10.1079\/9781786394583.0084"},{"key":"e_1_2_11_25_1","unstructured":"AEMPS Mirtzapine technical sheet. Available from:https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/67068\/FT_67068.html"}],"container-title":["Veterinary Record"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bvajournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/vetr.3670","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:46:05Z","timestamp":1761630365000},"score":1,"resource":{"primary":{"URL":"https:\/\/bvajournals.onlinelibrary.wiley.com\/doi\/10.1002\/vetr.3670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,11]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,4,20]]}},"alternative-id":["10.1002\/vetr.3670"],"URL":"https:\/\/doi.org\/10.1002\/vetr.3670","archive":["Portico"],"relation":{},"ISSN":["0042-4900","2042-7670"],"issn-type":[{"value":"0042-4900","type":"print"},{"value":"2042-7670","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,11]]},"article-number":"e3670"}}